Jul 2026· Stem Cell Reviews and Reports· Vol 22, pp. 3152 - 3171· 0 citations· 126 references
Medicine
TL;DR
An integrated framework linking LCSC niche regulation with nanotechnology-based precision therapeutics in lung cancer is established, and the therapeutic potential of multifunctional nanoplatforms is highlighted in modulating stemness-associated pathways, overcoming immune suppression, and disrupting metabolic adaptation.
Overall, siRNA-based strategies may play a crucial role in the future development of precision-oriented therapeutic frameworks in GC research, and this review emphasizes the integration of molecular target selection with delivery system design in a GC-specific context.
Gheysar Seifollahnezhad, B. Erdağ· Experimental oncology· 0 citations
This review critically examines recent advances in nanotechnology-enabled targeting of CAFs and immune suppression within the TME, and concludes that nanotechnology-driven TME modulation represents a promising paradigm shift toward more durable and effective cancer therapies.
Muhindo Edgar· NEWPORT INTERNATIONAL JOURNA...· 0 citations
Nanoparticle‐based therapies are a unique new frontier in breast cancer therapy, have considerable clinical potential, offer promise for patient‐specific treatment, and warrant further investigation in breast cancer, particularly in advanced targeting mechanisms, multifunctional approaches, and individualized intervent...
Sina M Matalqah, Laila M Matalqah, Abdel Rahman Al Tawaha et al.· International Journal of Bre...· 3 citations
This comprehensive review provides details on nanocarriers and their loaded delivery systems as effective strategies for breast cancer treatment and provides an updated synthesis of nanocarrier-based approaches, focusing on recent clinical and preclinical innovations in drug delivery, diagnostics, and personalized medi...
Prerana Sahu, G. Sahu, Harish Sharma et al.· Current Cancer Therapy Revie...· 0 citations
Future studies must aim to design nanoparticles that maximize tumor uptake, incorporate predictive biomarkers, and optimize clinical utility and therapeutic efficacy to enhance translational success.
A. Singh, Shatrudhan Prajapati, Shikha Yadav et al.· Current Pharmacogenomics and...· 0 citations
This review outlines the recent developments of lipid nanoparticles for TNBC, including liposomes, solid lipid nanoparticles, nanostructured lipid carriers, lipidpolymer hybrids, ionizable lipid nanoparticles, and biomimetic vesicles.
Issac V. Cherian, Harpreet Kaur, Kamre Aalam et al.· Nano LIFE· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
